A possible quality of MVP overexpression as predictive marker for GBM responsiveness to EGFR, PI3K or mTOR targeting agents, as suggested by our transgenic cell models, needs to be addressed using well-characterized patient material from controlled clinical studies. Here, EGFR is linked to glioblastoma.